The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
<p>Abstract</p> <p>Background</p> <p>The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks.</p&...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-07-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | http://www.dmsjournal.com/content/4/1/36 |
| _version_ | 1819117798339641344 |
|---|---|
| author | Frederich Robert McNeill Robert Berglind Niklas Fleming Douglas Chen Roland |
| author_facet | Frederich Robert McNeill Robert Berglind Niklas Fleming Douglas Chen Roland |
| author_sort | Frederich Robert |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks.</p> <p>Methods</p> <p>365 treatment-naïve patients with T2DM (HbA<sub>1c</sub> 7.0%–10.0%) were treated with saxagliptin 2.5 mg q.A.M., saxagliptin 2.5 mg q.A.M. with possible titration to saxagliptin 5 mg, saxagliptin 5 mg q.A.M., saxagliptin 5 mg q.P.M., or placebo. After week 24, patients in all groups were eligible for titration to saxagliptin 10 mg based on HbA<sub>1c</sub> ≥7%, and all unrescued placebo patients began blinded metformin 500 mg/day. Rescue with open-label metformin was available for patients with inadequate glycemic control.</p> <p>Results</p> <p>At week 24, placebo-subtracted mean HbA<sub>1c</sub> reduction from baseline (LOCF) was significantly greater in the saxagliptin treatment groups vs placebo, and remained greater through week 76. Serious adverse events (AEs) and discontinuations due to AEs were similar in saxagliptin and control groups; incidence of confirmed hypoglycemia was low across all treatment groups (saxagliptin-treated, 2 [0.7]; control, 1 [1.4]).</p> <p>Conclusions</p> <p>In treatment-naïve patients with T2DM, saxagliptin monotherapy demonstrated statistically significant improvement in HbA<sub>1c</sub> compared with placebo at 24 weeks and was generally well tolerated for up to 76 weeks.</p> <p>Trial registration</p> <p>ClinicalTrials.gov Identifier: NCT00316082</p> |
| first_indexed | 2024-12-22T05:38:42Z |
| format | Article |
| id | doaj.art-76acc4cb65d44b55a6d261e6d82399f7 |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-12-22T05:38:42Z |
| publishDate | 2012-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-76acc4cb65d44b55a6d261e6d82399f72022-12-21T18:37:16ZengBMCDiabetology & Metabolic Syndrome1758-59962012-07-01413610.1186/1758-5996-4-36The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trialFrederich RobertMcNeill RobertBerglind NiklasFleming DouglasChen Roland<p>Abstract</p> <p>Background</p> <p>The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks.</p> <p>Methods</p> <p>365 treatment-naïve patients with T2DM (HbA<sub>1c</sub> 7.0%–10.0%) were treated with saxagliptin 2.5 mg q.A.M., saxagliptin 2.5 mg q.A.M. with possible titration to saxagliptin 5 mg, saxagliptin 5 mg q.A.M., saxagliptin 5 mg q.P.M., or placebo. After week 24, patients in all groups were eligible for titration to saxagliptin 10 mg based on HbA<sub>1c</sub> ≥7%, and all unrescued placebo patients began blinded metformin 500 mg/day. Rescue with open-label metformin was available for patients with inadequate glycemic control.</p> <p>Results</p> <p>At week 24, placebo-subtracted mean HbA<sub>1c</sub> reduction from baseline (LOCF) was significantly greater in the saxagliptin treatment groups vs placebo, and remained greater through week 76. Serious adverse events (AEs) and discontinuations due to AEs were similar in saxagliptin and control groups; incidence of confirmed hypoglycemia was low across all treatment groups (saxagliptin-treated, 2 [0.7]; control, 1 [1.4]).</p> <p>Conclusions</p> <p>In treatment-naïve patients with T2DM, saxagliptin monotherapy demonstrated statistically significant improvement in HbA<sub>1c</sub> compared with placebo at 24 weeks and was generally well tolerated for up to 76 weeks.</p> <p>Trial registration</p> <p>ClinicalTrials.gov Identifier: NCT00316082</p>http://www.dmsjournal.com/content/4/1/36DPP-4 inhibitorMonotherapySaxagliptinTitrationType 2 diabetes mellitus |
| spellingShingle | Frederich Robert McNeill Robert Berglind Niklas Fleming Douglas Chen Roland The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial Diabetology & Metabolic Syndrome DPP-4 inhibitor Monotherapy Saxagliptin Titration Type 2 diabetes mellitus |
| title | The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial |
| title_full | The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial |
| title_fullStr | The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial |
| title_full_unstemmed | The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial |
| title_short | The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial |
| title_sort | efficacy and safety of the dipeptidyl peptidase 4 inhibitor saxagliptin in treatment naive patients with type 2 diabetes mellitus a randomized controlled trial |
| topic | DPP-4 inhibitor Monotherapy Saxagliptin Titration Type 2 diabetes mellitus |
| url | http://www.dmsjournal.com/content/4/1/36 |
| work_keys_str_mv | AT frederichrobert theefficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT mcneillrobert theefficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT berglindniklas theefficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT flemingdouglas theefficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT chenroland theefficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT frederichrobert efficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT mcneillrobert efficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT berglindniklas efficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT flemingdouglas efficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial AT chenroland efficacyandsafetyofthedipeptidylpeptidase4inhibitorsaxagliptinintreatmentnaivepatientswithtype2diabetesmellitusarandomizedcontrolledtrial |